British insurer AXA Health will not pay for Wegovy weight-loss treatment

British private insurer AXA Health has said it will not pay for treatment with Novo Nordisk's weight-loss drug Wegovy, which launched in the UK on Monday.

AXA Health told Reuters in a statement: "As it stands, AXA Health would not cover the use of Wegovy as this would be prescribed as an outpatient drug for a chronic condition".

It declined to say how many people in the UK it insures, citing commercial sensitivity.